Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly announces Acapulco trial results

Eli Lilly announces Acapulco trial results

5th September 2008

Eli Lilly has announced the results of the latest study comparing prasugrel with clopidogrel.

In the new crossover Acapulco study, prasugel was found to significantly reduce platelet aggregation in patients with acute coronary syndrome when compared to clopidogrel at high doses.

The trial results showed that patients administered with a 900mg loading dose of clopidogel experienced a better inhibition of platelet aggregation and blood clot formation if administered with a 10mg maintenance dose of prasugrel, rather than a 150mg dose of clopidogrel.

Eli Lilly said platelets play a key role in acute coronary syndrome as they can form blood clots that potentially occlude coronary arteries and may lead to cardiac events.

Prasugrel is an investigational orally-administered antiplatelet compound developed by Daiichi Sankyo and Ube Industries, its Japanese research partner.

Professor Gilles Montalescot from the University Hospital Pitie-Salpetriere, Paris, France, said: “This study provides the first evidence of the greater antiplatelet effect of a 10mg prasugrel maintenance dose versus a 150mg clopidogrel maintenance dose following a 900mg loading dose of clopidogrel.”

Earlier this week, Eli Lilly announced the results of the latest subanalysis of the Trition-Timi 38 trial comparing prasugrel with clopidogrel in patients following percutaneous coronary intervention.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.